Source:http://linkedlifedata.com/resource/pubmed/id/11526158
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
2001-8-29
|
| pubmed:abstractText |
VITEK 2 is a new automatic system for the identification and susceptibility testing of the most clinically important bacteria. In the present study 198 clinical isolates, including Pseudomonas aeruginosa (n = 146), Acinetobacter baumannii (n = 25), and Stenotrophomonas maltophilia (n = 27) were evaluated. Reference susceptibility testing of cefepime, cefotaxime, ceftazidime, ciprofloxacin, gentamicin, imipenem, meropenem, piperacillin, tobramycin, levofloxacin (only for P. aeruginosa), co-trimoxazole (only for S. maltophilia), and ampicillin-sulbactam and tetracycline (only for A. baumannii) was performed by microdilution (NCCLS guidelines). The VITEK 2 system correctly identified 91.6, 100, and 76% of P. aeruginosa, S. maltophilia, and A. baumannii isolates, respectively, within 3 h. The respective percentages of essential agreement (to within 1 twofold dilution) for P. aeruginosa and A. baumannii were 89.0 and 88.0% (cefepime), 91.1 and 100% (cefotaxime), 95.2 and 96.0% (ceftazidime), 98.6 and 100% (ciprofloxacin), 88.4 and 100% (gentamicin), 87.0 and 92.0% (imipenem), 85.0 and 88.0% (meropenem), 84.2 and 96.0% (piperacillin), and 97.3 and 80% (tobramycin). The essential agreement for levofloxacin against P. aeruginosa was 86.3%. The percentages of essential agreement for ampicillin-sulbactam and tetracycline against A. baumannii were 88.0 and 100%, respectively. Very major errors for P. aeruginosa (resistant by the reference method, susceptible with the VITEK 2 system [resistant to susceptible]) were noted for cefepime (0.7%), cefotaxime (0.7%), gentamicin (0.7%), imipenem (1.4%), levofloxacin (2.7%), and piperacillin (2.7%) and, for one strain of A. baumannii, for imipenem. Major errors (susceptible to resistant) were noted only for P. aeruginosa and cefepime (2.0%), ceftazidime (0.7%), and piperacillin (3.4%). Minor errors ranged from 0.0% for piperacillin to 22.6% for cefotaxime against P. aeruginosa and from 0.0% for piperacillin and ciprofloxacin to 20.0% for cefepime against A. baumannii. The VITEK 2 system provided co-trimoxazole MICs only for S. maltophilia; no very major or major errors were obtained for co-trimoxazole against this species. It is concluded that the VITEK 2 system allows the rapid identification of S. maltophilia and most P. aeruginosa and A. baumannii isolates. The VITEK 2 system can perform reliable susceptibility testing of many of the antimicrobial agents used against P. aeruginosa and A. baumannii. It would be desirable if new versions of the VITEK 2 software were able to determine MICs and the corresponding clinical categories of agents active against S. maltophilia.
|
| pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/11526158-10066525,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11526158-10203497,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11526158-10655347,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11526158-10952561,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11526158-1295766,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11526158-1329641,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11526158-1498768,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11526158-1624575,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11526158-1822083,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11526158-1909714,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11526158-2199522,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11526158-2799067,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11526158-7814505,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11526158-7929770,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11526158-8379542,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11526158-8654449,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11526158-9230393,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11526158-9650942,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11526158-9823533
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0095-1137
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
39
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
3247-53
|
| pubmed:dateRevised |
2009-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:11526158-Acinetobacter,
pubmed-meshheading:11526158-Anti-Bacterial Agents,
pubmed-meshheading:11526158-Bacterial Typing Techniques,
pubmed-meshheading:11526158-Bacteriological Techniques,
pubmed-meshheading:11526158-Gram-Negative Aerobic Rods and Cocci,
pubmed-meshheading:11526158-Gram-Negative Bacterial Infections,
pubmed-meshheading:11526158-Humans,
pubmed-meshheading:11526158-Microbial Sensitivity Tests,
pubmed-meshheading:11526158-Pseudomonas aeruginosa,
pubmed-meshheading:11526158-Reagent Kits, Diagnostic,
pubmed-meshheading:11526158-Stenotrophomonas
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Evaluation of the VITEK 2 system for the identification and susceptibility testing of three species of nonfermenting gram-negative rods frequently isolated from clinical samples.
|
| pubmed:affiliation |
Department of Microbiology, School of Medicine, University of Seville, Seville, Spain.
|
| pubmed:publicationType |
Journal Article,
Evaluation Studies
|